Richard Ceska

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3612579/publications.pdf

Version: 2024-02-01

113 papers	7,537 citations	147801 31 h-index	51608 86 g-index
141 all docs	141 docs citations	141 times ranked	7541 citing authors

#	Article	IF	Citations
1	Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events. New England Journal of Medicine, 2015, 372, 1489-1499.	27.0	1,838
2	A 52-Week Placebo-Controlled Trial of Evolocumab in Hyperlipidemia. New England Journal of Medicine, 2014, 370, 1809-1819.	27.0	607
3	Effect of Evolocumab or Ezetimibe Added to Moderate- or High-Intensity Statin Therapy on LDL-C Lowering in Patients With Hypercholesterolemia. JAMA - Journal of the American Medical Association, 2014, 311, 1870.	7.4	422
4	Efficacy and Tolerability of Evolocumab vs Ezetimibe in Patients With Muscle-Related Statin Intolerance. JAMA - Journal of the American Medical Association, 2016, 315, 1580.	7.4	420
5	ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia. European Heart Journal, 2015, 36, ehv370.	2.2	395
6	Dose-Ranging Effects of Canagliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, as Add-On to Metformin in Subjects With Type 2 Diabetes. Diabetes Care, 2012, 35, 1232-1238.	8.6	372
7	The Residual Risk Reduction Initiative: A Call to Action to Reduce Residual Vascular Risk in Patients with Dyslipidemia. American Journal of Cardiology, 2008, 102, 1K-34K.	1.6	371
8	Position paper Statin intolerance â€“ an attempt at a unified definition. Position paper from an International Lipid Expert Panel. Archives of Medical Science, 2015, 1, 1-23.	0.9	311
9	Age and residual cholesterol efflux affect HDL cholesterol levels and coronary artery disease in ABCA1 heterozygotes. Journal of Clinical Investigation, 2000, 106, 1263-1270.	8.2	295
10	The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidaemic patients. Diabetes and Vascular Disease Research, 2008, 5, 319-335.	2.0	227
11	Randomized, Placebo-Controlled Trial of Mipomersen in Patients with Severe Hypercholesterolemia Receiving Maximally Tolerated Lipid-Lowering Therapy. PLoS ONE, 2012, 7, e49006.	2.5	190
12	Editorial. American Journal of Cardiology, 1998, 81, 912-917.	1.6	187
13	Both fenofibrate and atorvastatin improve vascular reactivity in combined hyperlipidaemia (fenofibrate versus atorvastatin trial â€" FAT). Cardiovascular Research, 2001, 52, 290-298.	3.8	131
14	Statin intolerance â€“ an attempt at a unified definition. Position paper from an International Lipid Expert Panel. Expert Opinion on Drug Safety, 2015, 14, 935-955.	2.4	117
15	The selective peroxisome proliferator-activated receptor alpha modulator (SPPARMÎ±) paradigm: conceptual framework and therapeutic potential. Cardiovascular Diabetology, 2019, 18, 71.	6.8	104
16	Eprotirome in patients with familial hypercholesterolaemia (the AKKA trial): a randomised, double-blind, placebo-controlled phase 3 study. Lancet Diabetes and Endocrinology,the, 2014, 2, 455-463.	11.4	84
17	The use of statins in people at risk of developing diabetes mellitus: Evidence and guidance for clinical practice. Atherosclerosis Supplements, 2014, 15, 1-15.	1.2	83
18	Cholesterol-lowering therapy evokes time-limited changes in serotonergic transmission. Psychiatry Research, 2005, 133, 197-203.	3.3	78

#	Article	IF	Citations
19	An Exploratory Analysis of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition and Aortic Stenosis in the FOURIER Trial. JAMA Cardiology, 2020, 5, 709.	6.1	63
20	Folate supplementation prevents plasma homocysteine increase after fenofibrate therapy. Nutrition, 2001, 17, 721-723.	2.4	57
21	Comparison of the effects of atorvastatin or fenofibrate on nonlipid biochemical risk factors and the LDL particle size in subjects with combined hyperlipidemia. American Heart Journal, 2002, 144, E6.	2.7	56
22	Drugâ€“drug interactions with statins: will pitavastatin overcome the statinsâ€™ Achillesâ€™ heel?. Current Medical Research and Opinion, 2011, 27, 1551-1562.	1.9	55
23	Ultrasound protocols to measure carotid intima-media thickness in trials; comparison of reproducibility, rate of progression, and effect of intervention in subjects with familial hypercholesterolemia and subjects with mixed dyslipidemia. Annals of Medicine, 2010, 42, 447-464.	3.8	49
24	T-1131â†'C polymorphism within the apolipoprotein AV gene in hypertriglyceridemic individuals. Atherosclerosis, 2003, 167, 369-370.	0.8	48
25	Statin-Associated Myopathy: From Genetic Predisposition to Clinical Management. Physiological Research, 2014, 63, S327-S334.	0.9	45
26	Statin Intolerance: the Clinicianâ€™s Perspective. Current Atherosclerosis Reports, 2015, 17, 69.	4.8	43
27	Oral but not transdermal estrogen replacement therapy changes the composition of plasma lipoproteins. Metabolism: Clinical and Experimental, 2008, 57, 1088-1092.	3.4	42
28	FTO and MC4R gene variants determine BMI changes in children after intensive lifestyle intervention. Clinical Biochemistry, 2013, 46, 313-316.	1.9	39
29	Impact of apolipoprotein A5 variants on statin treatment efficacy. Pharmacogenomics, 2009, 10, 945-950.	1.3	38
30	Effect of simvastatin and fenofibrate on endothelium in Type 2 diabetes. European Journal of Pharmacology, 2004, 493, 183-189.	3.5	35
31	Stepâ€byâ€step diagnosis and management of the nocebo/drucebo effect in statinâ€associated muscle symptoms patients: a position paper fromthe International Lipid Expert Panel(ILEP). Journal of Cachexia, Sarcopenia and Muscle, 2022, 13, 1596-1622.	7.3	35
32	Comparison of <scp>PCSK9</scp> Inhibitor Evolocumab vs Ezetimibe in Statinâ€Intolerant Patients: Design of the Goal Achievement After Utilizing an Antiâ€<scp>PCSK9</scp> Antibody in Statinâ€Intolerant Subjects 3 (<scp>GAUSS</scp>â€3) Trial. Clinical Cardiology, 2016, 39, 137-144.	1.8	32
33	Effect of atorvastatin and fenofibrate on autonomic tone in subjects with combined hyperlipidemia. American Journal of Cardiology, 2003, 92, 337-341.	1.6	31
34	MLXIPL variant in individuals with low and high triglyceridemia in white population in Central Europe. Human Genetics, 2008, 124, 553-555.	3.8	28
35	Efficacy and safety of extended-release niacin/laropiprant plus statin vs. doubling the dose of statin in patients with primary hypercholesterolaemia or mixed dyslipidaemia. International Journal of Clinical Practice, 2010, 64, 727-738.	1.7	27
36	Serum leptin levels in patients with hyperlipidemias. Nutrition, 2000, 16, 429-433.	2.4	26

#	Article	IF	Citations
37	Increased levels of pregnancy-associated plasma protein-A in patients with hypercholesterolemia: the effect of atorvastatin treatment. American Heart Journal, 2003, 146, 1060-1063.	2.7	26
38	Ser19->Trp polymorphism within the apolipoprotein AV gene in hypertriglyceridaemic people. Journal of Medical Genetics, 2003, 40, 105e-105.	3.2	25
39	SLCO1B1 Polymorphism is not associated with Risk of Statin-Induced Myalgia/Myopathy in a Czech Population. Medical Science Monitor, 2015, 21, 1454-1459.	1.1	24
40	Effect of folic acid on fenofibrate-induced elevation of homocysteine and cysteine. American Heart Journal, 2003, 146, 110A-115A.	2.7	22
41	Treatment of Hypertriglyceridemia: a Review of Current Options. Physiological Research, 2015, 64, S331-S340.	0.9	22
42	Familial Hypercholesterolemia in the Czech Republic: More Than 17 Years of Systematic Screening Within the MedPed Project. Physiological Research, 2017, 66, S1-S9.	0.9	21
43	Microvascular reactivity in patients with hypercholesterolemia: effect of lipid lowering treatment. Physiological Research, 2003, 52, 439-45.	0.9	21
44	Impact of Variants Within Seven Candidate Genes on Statin Treatment Efficacy. Physiological Research, 2012, 61, 609-617.	0.9	20
45	Clinical implications of the metabolic syndrome. Diabetes and Vascular Disease Research, 2007, 4, S2-S4.	2.0	18
46	Statin therapy in athletes and patients performing regular intense exercise â€“ Position paper from the International Lipid Expert Panel (ILEP). Pharmacological Research, 2020, 155, 104719.	7.1	17
47	Efficacy and Safety of K-877 (Pemafibrate), a Selective PPARÎ± Modulator, in European Patients on Statin Therapy. Diabetes Care, 2022, 45, 898-908.	8.6	17
48	Ivabradine in Stable Coronary Artery Disease. New England Journal of Medicine, 2014, 371, 2435-2435.	27.0	16
49	Gene variants at FTO, 9p21, and 2q36.3 are age-independently associated with myocardial infarction in Czech men. Clinica Chimica Acta, 2016, 454, 119-123.	1.1	15
50	Hypertriglyceridemia: Interaction between APOE and APOAV Variants. Clinical Chemistry, 2005, 51, 1311-1313.	3.2	14
51	Detection of variability in apo(a) gene transcription regulatory sequences using the DGGE method. Clinica Chimica Acta, 2007, 376, 77-81.	1.1	13
52	The Impact of the International Cooperation On Familial Hypercholesterolemia Screening and Treatment: Results from the ScreenPro FH Project. Current Atherosclerosis Reports, 2019, 21, 36.	4.8	13
53	APOA5 Ala315>Val, identified in patients with severe hypertriglyceridemia, is a common mutation with no major effects on plasma lipid levels. Clinical Chemistry and Laboratory Medicine, 2008, 46, 773-7.	2.3	12
54	Comparison of the effects of atorvastatin or fenofibrate on nonlipid biochemical risk factors and the LDL particle size in subjects with combined hyperlipidemia. American Heart Journal, 2002, 144, G1-G8.	2.7	11

#	Article	IF	Citations
55	Association between polymorphism within the RYR2 receptor and development of statin-associated myalgia/myopathy in the Czech population. European Journal of Internal Medicine, 2015, 26, 367-368.	2.2	11
56	The Gene Score for Predicting Hypertriglyceridemia: New Insights from a Czech Caseâ€“Control Study. Molecular Diagnosis and Therapy, 2019, 23, 555-562.	3.8	10
57	The Impact of Physical Activity and Dietary Measures on the Biochemical and Anthropometric Parameters in Obese Children. Is There Any Genetic Predisposition?. Central European Journal of Public Health, 2015, 23, S62-S66.	1.1	10
58	Hyperlipidemia is associated with altered levels of insulin-like growth factor-I. Physiological Research, 2008, 57, 919-925.	0.9	10
59	A comprehensive guidelines-based approach reduces cardiovascular risk in everyday practice: the VARO study. Archives of Medical Science, 2017, 4, 705-710.	0.9	9
60	Apoe genotype is not associated with variations in bone mineral density. Atherosclerosis, 1999, 144, 103-104.	0.8	8
61	PAPP-A, a novel marker of unstable plaque, is not influenced by hypolipidemic treatment in contrast to CRP. Atherosclerosis, 2003, 166, 195-196.	0.8	8
62	Atorvastatin reduces expression of leukocyte adhesion molecules in patients with hypercholesterolemia. Atherosclerosis, 2003, 166, 197-198.	0.8	8
63	Nitroglycerin Induced Syncope Occurs in Subjects with Delayed Phase Shift of Baroreflex Action. PACE - Pacing and Clinical Electrophysiology, 2002, 25, 828-832.	1.2	7
64	Increase of inflammatory state in overweight adults with combined hyperlipidemia. Nutrition, Metabolism and Cardiovascular Diseases, 2003, 13, 227-231.	2.6	7
65	Effect of rosiglitazone on homocysteine and creatinine levels in patients with type 2 diabetes. Atherosclerosis, 2005, 183, 367-368.	0.8	7
66	Combined therapy of mixed dyslipidemia in patients with high cardiovascular risk and changes in the lipid target values and atherogenic index of plasma. Cor Et Vasa, 2014, 56, e133-e139.	0.1	7
67	Body Adiposity Changes After Lifestyle Interventions in Children/Adolescents and the NYD-SP18 and TMEM18 Variants. Medical Science Monitor, 2018, 24, 7493-7498.	1.1	7
68	Familial defective apolipoprotein B-100 homozygote with premature coronary atherosclerosis. A case report 1. Journal of Internal Medicine, 1999, 246, 235-236.	6.0	6
69	The apo(a) gene (TTTTA)n promoter polymorphism and its association with variability in exons of the kringle IV types 8 to 10. Clinica Chimica Acta, 2009, 405, 39-42.	1.1	6
70	Rosiglitazone Influences the Expression of Leukocyte Adhesion Molecules and CD14 Receptor in Type 2 Diabetes Mellitus Patients. Physiological Research, 2014, 63, S293-S298.	0.9	6
71	ScreenPro FH: From the Czech MedPed to International Collaboration. ScreenPro FH Is a Participating Project of the EAS-FHCS. Physiological Research, 2017, 66, S85-S90.	0.9	6
72	Apolipoprotein AV gene polymorphisms (T-1131/C and Ser19/Trp) influence plasma triglyceride levels and risk of myocardial infarction. Experimental and Clinical Cardiology, 2003, 8, 151-4.	1.3	6

#	Article	IF	Citations
73	Possible gene-gender interaction between the SLCO1B1 polymorphism and statin treatment efficacy. Neuroendocrinology Letters, 2012, 33 Suppl 2, 22-5.	0.2	6
74	PCSK9 Inhibitors in Real-world Practice: Analysis of Data from 314 Patients and 2 Years of Experience in a Center of Preventive Cardiology. Current Atherosclerosis Reports, 2022, , 1.	4.8	6
75	Decreasing Common Carotid Artery Intimal Thickness During Hypolipidemic Therapy. Angiology, 1997, 48, 761-767.	1.8	5
76	Type III hyperlipoproteinaemia and primary amenorrhoea associated with severe hypothyroidism. Acta Paediatrica, International Journal of Paediatrics, 2000, 89, 1023-1024.	1.5	5
77	Interaction of common sequence variants and selected risk factors in determination of HDL cholesterol levels. Clinical Biochemistry, 2010, 43, 754-758.	1.9	4
78	Plasma HDL-cholesterol and triglyceride levels in familial hypercholesterolemia: Data from the MedPed CZ database and the Czech population. Clinica Chimica Acta, 2011, 412, 920-924.	1.1	4
79	Variant within CELSR2/PSRC1/SORT1, but not within CILP2/PBX4, PCSK9 and APOB genes, has a potential to influence statin treatment efficacy. Journal of Applied Biomedicine, 2012, 10, 19-28.	1.7	4
80	APOA5 haplotypes determine triglyceride decrease after lifestyle induced weight loss in children. Nutrition, Metabolism and Cardiovascular Diseases, 2012, 22, e22-e23.	2.6	4
81	Statins, Glycemia, and Diabetes Mellitus: Another Point of View. Current Atherosclerosis Reports, 2014, 16, 458.	4.8	4
82	Statin Intolerance in Clinical Practice. Current Atherosclerosis Reports, 2020, 22, 27.	4.8	4
83	Familial Hypercholesterolemia: Real-World Data of 1236 Patients Attending a Czech Lipid Clinic. A Retrospective Analysis of Experience in More than 50 years. Part I: Genetics and Biochemical Parameters. Frontiers in Genetics, 2022, 13, 849008.	2.3	4
84	Variability in apo(a) gene regulatory sequences, compound genotypes, and association with Lp(a) plasma levels. Clinical Biochemistry, 2007, 40, 802-805.	1.9	3
85	Hypolipidemic drugs, blood pressure, heart rate, heart rate variability and sympathetic activity. International Congress Series, 2004, 1262, 458-461.	0.2	2
86	Prevention of diabetes with rosiglitazone: Evidence of benefit or unexpected harm?. Medical Hypotheses, 2008, 70, 199-200.	1.5	2
87	IMPACT OF APOLIPOPROTEIN A5 GENE VARIANTS ON STATIN TREATMENT EFFICACY. Atherosclerosis Supplements, 2008, 9, 40.	1.2	2
88	Ivabradine, Coronary Heart Disease, and Heart Failure: Time for Reappraisal. Current Atherosclerosis Reports, 2014, 16, 463.	4.8	2
89	Strong Association between APOA5 Gene Polymorphisms and Hypertriglyceridaemic Episodes. Folia Biologica, 2019, 65, 188-194.	0.6	2
90	Flow-Dependent Vasomotor Dysfunction of the Popliteal Artery Related to Common Carotid Artery Intima-Media Thickness. Angiology, 2001, 52, 689-695.	1.8	1

#	Article	IF	Citations
91	T06-P-019 Apolipoprotein E gene polymorphism in the Mongolian population. Atherosclerosis Supplements, 2005, 6, 169.	1.2	1
92	Folic acid does not improve surrogate markers of early atherosclerosis in atorvastatin-treated patients. Nutrition Research, 2007, 27, 181-185.	2.9	1
93	Statin therapy is a major determinant of PCSK9 plasma concentration: data from four clinical trials with AMG 145. European Heart Journal, 2013, 34, P681-P681.	2.2	1
94	Fifteen years of active search for patients with familial hypercholesterolemia in the Czech Republic. Atherosclerosis, 2014, 235, e197.	0.8	1
95	Effect of APOE genotype on LDL cholesterol levels in FH and FDB patients: Is there sex-specifically protective genotype?. Atherosclerosis, 2016, 252, e40.	0.8	1
96	Implementation of Cardiovascular Disease Prevention Guidelines into Clinical Practice: an Unmet Challenge?. Current Pharmaceutical Design, 2015, 21, 1180-1184.	1.9	1
97	Familial Hypercholesterolemia: Real-World Data of 1236 Patients Attending a Czech Lipid Clinic. A Retrospective Analysis of Experience in More than 50Âyears. Part II. Clinical Characteristics. Frontiers in Genetics, 2022, 13, 849267.	2.3	1
98	1.P.161 The effect of stain therapy on common carotid artery intimal thickness in patients with familial hyperlipidemia. Atherosclerosis, 1997, 134, 50.	0.8	0
99	2.W13.5 FDB-100: Diagnosis, laboratory and clinical findings, possibilities of treatment. Experience from homozygous and heterozygous patients. Atherosclerosis, 1997, 134, 110-111.	0.8	0
100	Apolipoprotein E polymorphism in patients with different types of hyperlipidemia. Atherosclerosis, 1999, 144, 21.	0.8	0
101	Type III hyperlipoproteinaemia in patient with severe hypothyroidism accompanied by primary amenorrhoea. Atherosclerosis, 1999, 144, 158.	0.8	0
102	Use of the D19S394 tetranucleotide repeat in the diagnosis of familial hypercholesterolemia. Atherosclerosis, 1999, 144, 195-196.	0.8	0
103	The independent correlation of the impact of lipoprotein(a) levels and apolipoprotein E polymorphism on carotid artery intima thickness. Atherosclerosis, 2000, 151, 311.	0.8	0
104	New Strategies in the Treatment of Dyslipidemia: Do We Know How?. Seminars in Vascular Medicine, 2004, 4, 305-310.	2.1	0
105	W15-P-006 Effect of rosiglitazone on homocysteine and creatinine levels in patients with type 2 diabetes. Atherosclerosis Supplements, 2005, 6, 98.	1.2	0
106	Mo-P6:430 Lipoprotein (A), its relation to gene control regions. Atherosclerosis Supplements, 2006, 7, 140-141.	1.2	0
107	We-P11:117 Rosiglitazone improves quality of lipoproteins in patients with type 2 diabetes. Atherosclerosis Supplements, 2006, 7, 371.	1.2	0
108	Is it safe to combine PPAR agonists? A lesson from muraglitazar. Medical Hypotheses, 2006, 67, 669.	1.5	0

#	Article	IF	Citations
109	PO9-212 EFFECT OF ROSIGLITAZONE ON LEUKOCYTE EXPRESSION OF PROINFLAMMATORY AND PROTHROMBOTIC MOLECULES IN PATIENTS WITH TYPE 2 DIABETES. Atherosclerosis Supplements, 2007, 8, 69.	1.2	0
110	SLCO1B1 transporter polymorphism is not associated with risk of myopathy in Czech population. Atherosclerosis, 2014, 235, e256.	0.8	0
111	Therapy with the thyroid hormone receptor agonist eprotirome in patients with familial hypercholesterolemia: a randomised, double blind, placebo-controlled study. Atherosclerosis, 2014, 235, e12.	0.8	0
112	FH homozygote without cardiovascular disease at the age of 40. Atherosclerosis, 2015, 241, e112.	0.8	0
113	Comments on the most important and recent studies involving PCSK9i. Vnitrni Lekarstvi, 2018, 64, 1137-1141.	0.2	0